David Martin PhD
Stock Analyst at Bloom Burton
(4.79)
# 546
Out of 5,000 analysts
238
Total ratings
54.2%
Success rate
20%
Average return
Main Sectors:
Stocks Rated by David Martin PhD
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XENE Xenon Pharmaceuticals | Reiterated: Buy | $74 → $71 | $36.56 | +94.20% | 9 | Sep 21, 2026 | |
| ZYME Zymeworks | Reiterated: Buy | $36 → $37 | $27.50 | +34.55% | 14 | Aug 26, 2026 | |
| TSXV: RX BioSyent Inc. | Reiterated: Buy | $18.00 | $16.54 | +8.83% | 15 | Aug 24, 2026 | |
| AUPH Aurinia Pharmaceuticals | Upgraded: Buy | $15 → $21 | $16.41 | +27.97% | 35 | Aug 20, 2026 | |
| TSX: MBX Microbix Biosystems Inc. | Reiterated: Buy | $0.40 | $0.30 | +33.33% | 14 | Aug 14, 2026 | |
| TSX: APTX Apotex Health Corp. | Reiterated: Buy | $40.00 | $33.65 | +18.87% | 3 | Aug 13, 2026 | |
| TSX: HLS HLS Therapeutics Inc. | Reiterated: Buy | $12.00 | $3.95 | +203.80% | 51 | Aug 13, 2026 | |
| TSX: MDP Medexus Pharmaceuticals Inc. | Reiterated: Buy | $6.00 → $6.50 | $5.07 | +28.21% | 14 | Aug 12, 2026 | |
| TSX: GUD Knight Therapeutics Inc. | Reiterated: Buy | $12.00 | $10.09 | +18.93% | 29 | Aug 7, 2026 | |
| ASX: PYC PYC Therapeutics Limited | Reiterated: Buy | $5.00 | $2.91 | +71.82% | 4 | Aug 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19.66 | $11.45 | +71.69% | 6 | Aug 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $5.00 | $3.16 | +58.23% | 12 | Jul 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8.42 → $4.00 | $0.41 | +887.65% | 11 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $9 | $12.31 | -26.89% | 6 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $14 | $21.43 | -34.53% | 1 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20.20 → $19.00 | $18.13 | n/a | 3 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $1.00 | $0.16 | n/a | 2 | Jul 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $6.92 | $2.40 | n/a | 9 | Sep 8, 2020 |
Xenon Pharmaceuticals
Sep 21, 2026
Reiterated: Buy
Price Target: $74 → $71
Current: $36.56
Upside: +94.20%
Zymeworks
Aug 26, 2026
Reiterated: Buy
Price Target: $36 → $37
Current: $27.50
Upside: +34.55%
BioSyent Inc.
Aug 24, 2026
Reiterated: Buy
Price Target: $18.00
Current: $16.54
Upside: +8.83%
Aurinia Pharmaceuticals
Aug 20, 2026
Upgraded: Buy
Price Target: $15 → $21
Current: $16.41
Upside: +27.97%
Microbix Biosystems Inc.
Aug 14, 2026
Reiterated: Buy
Price Target: $0.40
Current: $0.30
Upside: +33.33%
Apotex Health Corp.
Aug 13, 2026
Reiterated: Buy
Price Target: $40.00
Current: $33.65
Upside: +18.87%
HLS Therapeutics Inc.
Aug 13, 2026
Reiterated: Buy
Price Target: $12.00
Current: $3.95
Upside: +203.80%
Medexus Pharmaceuticals Inc.
Aug 12, 2026
Reiterated: Buy
Price Target: $6.00 → $6.50
Current: $5.07
Upside: +28.21%
Knight Therapeutics Inc.
Aug 7, 2026
Reiterated: Buy
Price Target: $12.00
Current: $10.09
Upside: +18.93%
PYC Therapeutics Limited
Aug 5, 2026
Reiterated: Buy
Price Target: $5.00
Current: $2.91
Upside: +71.82%
Aug 3, 2026
Reiterated: Buy
Price Target: $19.66
Current: $11.45
Upside: +71.69%
Jul 31, 2026
Reiterated: Buy
Price Target: $5.00
Current: $3.16
Upside: +58.23%
Dec 11, 2025
Reiterated: Buy
Price Target: $8.42 → $4.00
Current: $0.41
Upside: +887.65%
Nov 19, 2025
Reiterated: Buy
Price Target: $9
Current: $12.31
Upside: -26.89%
Oct 21, 2025
Reiterated: Buy
Price Target: $14
Current: $21.43
Upside: -34.53%
Jul 18, 2025
Reiterated: Buy
Price Target: $20.20 → $19.00
Current: $18.13
Upside: n/a
Jul 6, 2025
Initiated Coverage: Buy
Price Target: $1.00
Current: $0.16
Upside: n/a
Sep 8, 2020
Upgraded: Buy
Price Target: $6.92
Current: $2.40
Upside: n/a